Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
5/25/23 | Artiva Biotherapeutics | AB-101 (Artiva) for Non-Hodgkin's Lymphoma (NHL) | Subscribers Only | Subscribers Only | Subscribers Only |
5/25/23 | Merck (MRK) | Reblozyl for Myelodysplastic Syndrome (MDS) | Subscribers Only | Subscribers Only | Subscribers Only |
5/25/23 | AstraZeneca (AZN) | Imjudo for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) | Subscribers Only | Subscribers Only | Subscribers Only |
5/25/23 | Roche (RHHBY) | Tecentriq for Colorectal Cancer (CRC) | Subscribers Only | Subscribers Only | Subscribers Only |
5/25/23 | Bristol Myers Squibb (BMY) | Breyanzi for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
05/26/23 | Subscribers Only | Subscribers Only | Regulatory - PDUFA/Approval Decision (U.S.) |
05/27/23 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
05/27/23 | Subscribers Only | Subscribers Only | Trial Data - Final Results |
Now - 05/30/23 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
Now - 05/30/23 | Subscribers Only | Subscribers Only | Regulatory - Approval Decision (Japan) |